{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-348468","form_type":"8-K","ticker":"CRIS","cik":"0001108205","company_name":"CURIS INC","filed_at":"2021-12-06T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.522594+00:00","generated_at":"2026-06-28T03:24:07.246750+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Curis appoints Dr. John A. Hohneker to Board of Directors","bullets":["Dr. Hohneker elected as Class II director on Dec 2, 2021, term until 2022 annual meeting.","Receives standard non-employee director compensation: one-time option for 25,000 shares vesting over 4 years.","Brings 30 years of drug development experience; former President/CEO of Anokion and President of R&D at FORMA Therapeutics.","Expected to help advance CA-4948 (IRAK4 inhibitor) toward potential approval and commercialization."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-348468","json":"https://secwatch.observer/filing/0001193125-21-348468.json","markdown":"https://secwatch.observer/filing/0001193125-21-348468.md","text":"https://secwatch.observer/filing/0001193125-21-348468.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1108205/000119312521348468/0001193125-21-348468-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1108205/000119312521348468/d270245d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T03:24:07.246750+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4edcc1eae1","claim":"John A. Hohneker, M.D. was elected as Director at CURIS INC.","evidence_excerpt":"On December 2, 2021, the Board of Directors (“Board”) of Curis, Inc. (the “Company”) elected John A. Hohneker, M.D., to serve as a class II director until the 2022 Annual Meeting of Stockholders and thereafter until his successor is duly elected and qualified.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1108205/000119312521348468/0001193125-21-348468-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}